No Data
Tandem Diabetes Care Announces Upcoming Conference Presentation
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Global Healthcare Conference on
Citi Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Raises Target Price to $57
Citi analyst Joanne Wuensch upgrades $Tandem Diabetes Care(TNDM.US)$ to a buy rating, and adjusts the target price from $38 to $57.According to TipRanks data, the analyst has a success rate of 62.2% a
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $55
Stifel analyst Mathew Blackman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and adjusts the target price from $45 to $55.According to TipRanks data, the analyst has a success rate of 4
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $75
Lake Street analyst Brooks O'Neil maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and adjusts the target price from $60 to $75.According to TipRanks data, the analyst has a success rate o
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Lake Street: Maintains Tandem Diabetes Care (TNDM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $75.00.
Lake Street: Maintains Tandem Diabetes Care (TNDM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $75.00.